Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo

Authors

John W. Steele, Mount Sinai School of Medicine
Soong H. Kim, Mount Sinai School of Medicine
John R. Cirrito, Washington University School of Medicine in St. Louis
Deborah K. Verges, Washington University School of Medicine in St. Louis
Jessica L. Restivo, Washington University School of Medicine in St. Louis
David Westaway, University of Alberta
Paul Fraser, University of Toronto
Peter St George Hyslop, University of Toronto
Mary Sano, Mount Sinai School of Medicine
Ilya Bezprozvanny, University of Texas Southwestern Medical Center at Dallas
Michelle E. Ehrlich, Mount Sinai School of Medicine
David M. Holtzman, Washington University School of Medicine in St. LouisFollow
Sam Gandy, Mount Sinai School of Medicine

Journal

Molecular Neurodegeneration

Publication Date

2009

Volume

4

Inclusive Pages

51

Document Type

Open Access Publication

Rights and Permissions

Molecular Neurodegeneration 2009, 4:51 http://www.molecularneurodegeneration.com/content/4/1/51 © 2009 Steele et al; licensee BioMed Central Ltd.

Recommended Citation

Steele, John W.; Kim, Soong H.; Cirrito, John R.; Verges, Deborah K.; Restivo, Jessica L.; Westaway, David; Fraser, Paul; Hyslop, Peter St George; Sano, Mary; Bezprozvanny, Ilya; Ehrlich, Michelle E.; Holtzman, David M.; and Gandy, Sam, "Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo." Molecular Neurodegeneration. 4, 51. (2009).
https://digitalcommons.wustl.edu/open_access_pubs/294